Brief Introduction:

• National Medical Insurance, Category B.

• Launched in 2005.

• National standard bulk supplier of rHuIL-11.

• Participated in the development and collaborative calibration of rHuIL-11 national reference standards.

Indications:

Severe thrombocytopenia with degree III and IV induced by chemotherapy to solid tumor and to non-marrow leukemia.

Academic progress

Guideline Express: Expert consensus for diagnosis and treatment of thrombocytopenia in adult critical illness in China

2020-03-11

Guideline Express: Chinese expert consensus on the diagnosis and treatment of chemotherapy-induced thrombocytopenia with acute leukemia

2020-03-10

Research Progress: Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukemia patients with chemotherapy-induced thrombocytopenia

2020-03-10

Guideline Express: Consensus on clinical diagnosis, treatment and prevention management of chemother induced thrombocytopenia in China (2018)

2020-03-10

Guideline Express: Chinese expert consensus on recombinant human interleukin-11 in clinical treatment of thrombocytopenia

2020-03-09